Forma Therapeutics Holdings, Inc.

The company's financials show resilient growth, with revenue advancing from $0.00 in Q3 2021 to $0.00 in Q2 2022. Gross profit remained healthy with margins at N/A in Q2 2022 compared to N/A in Q3 2021. Operating income hit -$51.99M last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$51.28M. Net income dropped to -$52.58M, while earnings per share reached -$1.10. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.